Table 6.

Strategy-other therapies in combination with immune checkpoint inhibitors.

Intervention	Strategy	Date	Status	Patient population	Phase	Study design	ClinicalTrials.gov identifier
Nivolumab + FPA008 (CSF1R inhibitor)	PD-1 inhibitor, Colony stimulating factor-1 receptor inhibitor	2 December 2015	Recruiting	Advanced pancreatic cancer	I	Arm 1- Phase 1a monotherapy Arm 2- Phase1a combination therapy to determine safety data Arm 3- Phase 1b combination therapy to determine clinical activity and safety profile	NCT02526017
Nivolumab + Ulocuplumab (anti- CXCR4)	PD-1 inhibitor, Anti alpha chemokine receptor 4	8 December 2015	Recruiting	Metastatic solid tumors	I/II	Combination arm in pancreatic cancer	NCT02472977
Pembrolizumab + AM0010	PD-1 inhibitor, PEGylated recombinant human IL-10	24 March 2015	Recruiting	Advanced solid tumor including pancreatic cancer	I	Combination therapy	NCT02009449
MPDL3280A + RO6895882(IL-2v with anti-CEA)	PD-L1 inhibitor, Variant of Interleukin-2 against Carcinoembryonic antigen	1 December 2015	Recruiting	Advanced solid tumors	I	Part 1- Dose Escalation RO6895882(IL-2v with anti-CEA) + MPDL3280A Part 2- Dose expansion	NCT02350673
Pembrolizumab+ Modified vaccinia virus Ankara virus	PD-1 inhibitor, Oncolytic virus	18 December 2015	Not recruiting	Solid tumors with failed prior therapy including PDAC	I	Combination therapy	NCT02432963